Clinical Trial Update: Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update on ruxolitinib for newly diagnosed bronchiolitis obliterans syndrome with hematologic malignancy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans Syndrome
• Hematologic Malignancy

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Bronchiolitis Obliterans Syndrome, Hematologic Malignancy | Phase 2 | Status: UNKNOWN